Solu Therapeutics Unveils Innovative Preclinical Data on STX-0712 for Leukaemia Treatment
Solu Therapeutics to Present Groundbreaking Preclinical Data at ASH Annual Meeting
In anticipation of the American Society of Hematology (ASH) Annual Meeting, Solu Therapeutics has announced the presentation of its first preclinical data regarding STX-0712. This innovative therapy aims to tackle chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML), two severe forms of blood cancer. Scheduled for December 7-10, 2024, in San Diego, California, the presentations will outline the promising findings derived from their research.
About STX-0712
STX-0712 is particularly notable as a CCR2-CyTAC™ (Chemokine Receptor Type 2 Cytotoxicity Targeting Chimera), designed to target CCR2, a G-protein coupled receptor that is abundantly expressed on malignant monocytes in CMML and AML. This selectivity is critical, as it allows for the targeted elimination of these cancerous cells without affecting healthy cells. Solu Therapeutics has developed STX-0712 with the goal of enhancing the therapeutic options available for patients suffering from these challenging conditions.
Presentation Details
Solu Therapeutics will showcase the research through two poster presentations:
- - Title: Ex-Vivo Evaluation of STX-0712 for the Treatment of Acute Myeloid Leukaemia
Time: 5:30 PM - 7:30 PM PT
Location: San Diego Convention Center, Halls G-H
Abstract Number: 1380
- - Title: Preclinical Evaluation of STX-0712 for Chronic Myelomonocytic Leukaemia
Time: 6:00 PM - 8:00 PM PT
Location: San Diego Convention Center, Halls G-H
Abstract Number: 2771
These sessions will provide insights into the findings of their research and the potential impact of STX-0712 on current treatment landscapes.
The Innovation Behind Solu Therapeutics
Founded with a mission to create revolutionary therapies, Solu Therapeutics is committed to leveraging its proprietary platforms, CyTAC and TicTAC, to develop medicines that effectively target disease-driving cells. The firm’s dedication to oncology and immunology showcases its innovative approach, aiming not only to create effective treatments but also to reshape how we view and approach cancer therapies overall.
With its focus on leveraging the binding capabilities of small molecules combined with the therapeutic power of biologics, Solu Therapeutics has positioned itself at the forefront of biotechnological advancements, particularly in hematologic cancers. The introduction of STX-0712 marks another step in their journey to addressing significant unmet medical needs for patients, particularly in a field where innovation is critical.
Conclusion
As the medical community prepares for the ASH Annual Meeting, all eyes will be on the presentations from Solu Therapeutics. The anticipation surrounding STX-0712 highlights the ongoing evolution in cancer treatment research and the crucial need for targeted therapeutics that address the root causes of diseases like CMML and AML. Stakeholders, healthcare professionals, and patients alike are eager to see how these new findings may translate into clinical applications in the near future. Solu Therapeutics remains dedicated to transforming these promising preclinical results into real-world therapies that can change lives.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.